Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.
Belgian value-added medicines developer Hyloris Pharmaceuticals says that the €15m ($16.4m) it has just raised through a funding round will give it the firepower it needs to pursue a series of 505(b)(2) hybrid applications in the US.
Announcing the results of the funding round, Hyloris said the €15m had come from “a mix of new and existing...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
